Literature DB >> 29623181

Dealing with uncertainty in the treatment of Helicobacter pylori.

Xavier Calvet1.   

Abstract

Helicobacter pylori treatment may be viewed as an uncertain situation, where current knowledge is insufficient to provide evidence-based recommendations for all possible scenarios. Evidence suggests that, under uncertainty conditions, a few simple rules of thumb tend to work better than complex algorithms. Overall, five evidence-based rules of thumb are suggested: (1) Use four drugs; (2) Use maximal acid inhibition; (3) Treat for 2 weeks; (4) Do not repeat antibiotics after treatment failure; and (5) If your treatment works locally, keep using it. These simple rules of thumb may help the reader to select the best alternative for a given patient, choosing between the heterogeneous recommendations provided by the many different consensus conferences on H. pylori treatment recently published.

Entities:  

Keywords:  Helicobacter pylori; treatment; uncertainty

Year:  2018        PMID: 29623181      PMCID: PMC5881993          DOI: 10.1177/2040622318758240

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


  48 in total

1.  A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection.

Authors:  X Calvet; N García; T López; J P Gisbert; E Gené; M Roque
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

2.  Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis.

Authors:  E Gené; X Calvet; R Azagra; J P Gisbert
Journal:  Aliment Pharmacol Ther       Date:  2003-05-01       Impact factor: 8.171

Review 3.  Clinical practice. Helicobacter pylori infection.

Authors:  Kenneth E L McColl
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

4.  Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.

Authors:  Nicole G Hunfeld; Ron A Mathot; Daan J Touw; Ron H van Schaik; Paul G Mulder; Paul F Franck; Ernst J Kuipers; William P Geus
Journal:  Br J Clin Pharmacol       Date:  2008-01-30       Impact factor: 4.335

5.  Randomized controlled study of a novel triple nitazoxanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection.

Authors:  Mona Ah Shehata; Raghda Talaat; Samah Soliman; Huda Elmesseri; Shaimaa Soliman; Sherief Abd-Elsalam
Journal:  Helicobacter       Date:  2017-05-19       Impact factor: 5.753

6.  Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.

Authors:  Y Sakurai; Y Mori; H Okamoto; A Nishimura; E Komura; T Araki; M Shiramoto
Journal:  Aliment Pharmacol Ther       Date:  2015-07-21       Impact factor: 8.171

7.  Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations.

Authors:  C Y Tay; H M Windsor; F Thirriot; W Lu; C Conway; T T Perkins; B J Marshall
Journal:  Aliment Pharmacol Ther       Date:  2012-10-16       Impact factor: 8.171

8.  Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy.

Authors:  Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Chise Kodaira; Masafumi Nishino; Mutsuhiro Ikuma; Takashi Ishizaki; Akira Hishida
Journal:  Helicobacter       Date:  2007-08       Impact factor: 5.753

9.  Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice.

Authors:  Adrian G McNicholl; Alicia C Marin; Javier Molina-Infante; Manuel Castro; Jesús Barrio; Julio Ducons; Xavier Calvet; Cristobal de la Coba; Miguel Montoro; Felipe Bory; Angeles Perez-Aisa; Montserrat Forné; Javier P Gisbert
Journal:  Gut       Date:  2013-05-11       Impact factor: 23.059

10.  Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.

Authors:  Zhiqiang Song; Liya Zhou; Jianzhong Zhang; Lihua He; Peng Bai; Yan Xue
Journal:  Dig Liver Dis       Date:  2016-01-15       Impact factor: 4.088

View more
  4 in total

1.  Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis.

Authors:  Olga P Nyssen; Marta Espada; Javier P Gisbert
Journal:  Front Microbiol       Date:  2022-06-14       Impact factor: 6.064

Review 2.  Clinical Factors Implicated in Antibiotic Resistance in Helicobacter pylori Patients.

Authors:  Brian White; Maria Winte; Joshua DeSipio; Sangita Phadtare
Journal:  Microorganisms       Date:  2022-01-29

3.  High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study.

Authors:  Llum Olmedo; Rafael Azagra; Amada Aguyé; Marta Pascual; Xavier Calvet; Emili Gené
Journal:  J Clin Med       Date:  2020-07-28       Impact factor: 4.241

4.  Antibiotics as a Stressing Factor Triggering the Harboring of Helicobacter pylori J99 within Candida albicans ATCC10231.

Authors:  Kimberly Sánchez-Alonzo; Libnny Belmar; Cristian Parra-Sepúlveda; Humberto Bernasconi; Víctor L Campos; Carlos T Smith; Katia Sáez; Apolinaria García-Cancino
Journal:  Pathogens       Date:  2021-03-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.